Japan city Tokyo covid-19 information infection Japan city Tokyo

Daiichi Sankyo to develop Nafamostat inhalation therapy for Covid-19

Reading now: 801
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.

Nafamostat is an injectable drug indicated in Japan for the treatment for acute pancreatitis and disseminated intravascular coagulation.

According to the data available so far, the drug is adequately safe. During the first stage of Covid-19 infection, the outer enveloped of SARS-CoV-2 fuses with the host cell surface membrane.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA